154 related articles for article (PubMed ID: 26253333)
1. Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone.
Acevedo C; Bale H; Gludovatz B; Wat A; Tang SY; Wang M; Busse B; Zimmermann EA; Schaible E; Allen MR; Burr DB; Ritchie RO
Bone; 2015 Dec; 81():352-363. PubMed ID: 26253333
[TBL] [Abstract][Full Text] [Related]
2. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.
Tang SY; Allen MR; Phipps R; Burr DB; Vashishth D
Osteoporos Int; 2009 Jun; 20(6):887-94. PubMed ID: 18850239
[TBL] [Abstract][Full Text] [Related]
3. The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate.
Bajaj D; Geissler JR; Allen MR; Burr DB; Fritton JC
Bone; 2014 Jul; 64():57-64. PubMed ID: 24704262
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties.
Ma S; Goh EL; Jin A; Bhattacharya R; Boughton OR; Patel B; Karunaratne A; Vo NT; Atwood R; Cobb JP; Hansen U; Abel RL
Sci Rep; 2017 Mar; 7():43399. PubMed ID: 28262693
[TBL] [Abstract][Full Text] [Related]
5. Duration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogs.
Burr DB; Liu Z; Allen MR
Bone; 2015 Feb; 71():58-62. PubMed ID: 25445446
[TBL] [Abstract][Full Text] [Related]
6. Effects of raloxifene and alendronate on non-enzymatic collagen cross-links and bone strength in ovariectomized rabbits in sequential treatments after daily human parathyroid hormone (1-34) administration.
Kimura S; Saito M; Kida Y; Seki A; Isaka Y; Marumo K
Osteoporos Int; 2017 Mar; 28(3):1109-1119. PubMed ID: 27796444
[TBL] [Abstract][Full Text] [Related]
7. Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk.
Burr DB; Diab T; Koivunemi A; Koivunemi M; Allen MR
J Orthop Res; 2009 Oct; 27(10):1288-92. PubMed ID: 19396816
[TBL] [Abstract][Full Text] [Related]
8. Short-term effects of bisphosphonates on the biomechanical properties of canine bone.
Wang X; Shanbhag AS; Rubash HE; Agrawal CM
J Biomed Mater Res; 1999 Mar; 44(4):456-60. PubMed ID: 10397950
[TBL] [Abstract][Full Text] [Related]
9. Effects of osteoporosis medications on bone quality.
Benhamou CL
Joint Bone Spine; 2007 Jan; 74(1):39-47. PubMed ID: 17196423
[TBL] [Abstract][Full Text] [Related]
10. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment.
Allen MR; Reinwald S; Burr DB
Calcif Tissue Int; 2008 May; 82(5):354-60. PubMed ID: 18463913
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antiosteoporotic effect of Lepidium sativum and alendronate in glucocorticoid-induced osteoporosis in Wistar rats.
Elshal MF; Almalki AL; Hussein HK; Khan JA
Afr J Tradit Complement Altern Med; 2013; 10(5):267-73. PubMed ID: 24311835
[TBL] [Abstract][Full Text] [Related]
12. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide.
Miyakoshi N; Aizawa T; Sasaki S; Ando S; Maekawa S; Aonuma H; Tsuchie H; Sasaki H; Kasukawa Y; Shimada Y
J Bone Miner Metab; 2015 Sep; 33(5):553-9. PubMed ID: 25227287
[TBL] [Abstract][Full Text] [Related]
13. Age-related changes in the plasticity and toughness of human cortical bone at multiple length scales.
Zimmermann EA; Schaible E; Bale H; Barth HD; Tang SY; Reichert P; Busse B; Alliston T; Ager JW; Ritchie RO
Proc Natl Acad Sci U S A; 2011 Aug; 108(35):14416-21. PubMed ID: 21873221
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
15. Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture.
Iizuka Y; Takechi R; Iizuka H; Omodaka T; Takagishi K
Skeletal Radiol; 2016 Oct; 45(10):1403-7. PubMed ID: 27402027
[TBL] [Abstract][Full Text] [Related]
16. Identification of material parameters based on Mohr-Coulomb failure criterion for bisphosphonate treated canine vertebral cancellous bone.
Wang X; Allen MR; Burr DB; Lavernia EJ; Jeremić B; Fyhrie DP
Bone; 2008 Oct; 43(4):775-80. PubMed ID: 18599390
[TBL] [Abstract][Full Text] [Related]
17. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.
Allen MR; Burr DB
J Bone Miner Res; 2007 Nov; 22(11):1759-65. PubMed ID: 17663638
[TBL] [Abstract][Full Text] [Related]
18. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.
Gomberg SJ; Wustrack RL; Napoli N; Arnaud CD; Black DM
J Clin Endocrinol Metab; 2011 Jun; 96(6):1627-32. PubMed ID: 21430030
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.
Miller PD; McCarthy EF
Semin Arthritis Rheum; 2015 Apr; 44(5):477-482. PubMed ID: 25312241
[TBL] [Abstract][Full Text] [Related]
20. Effect of alendronate administration on bone mineral density and bone strength in castrated rats.
Broulik PD; Rosenkrancová J; Růzicka P; Sedlácek R
Horm Metab Res; 2005 Jul; 37(7):414-8. PubMed ID: 16034712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
